Use of polylactic acid implants to correct facial lipoatrophy in human immunodeficiency virus 1-positive individuals receiving combination antiretroviral therapy

Archives of Dermatology

Volumn 142, Issue 3, 2006, Pages 329-334

  Cattelan, Anna Maria ^a   Bauer, Ute ^a   Trevenzoli, Marco ^a   Sasset, Lolita ^a   Campostrini, Stefano ^b   Facchin, Chiara ^a   Pagiaro, Emilio ^a   Gerzeli, Stefano ^b   Cadrobbi, Paolo ^a   Chiarelli, Angelo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ANTIRETROVIRUS AGENT; CORTICOSTEROID; DIDANOSINE; LAMIVUDINE; POLYLACTIC ACID; PROTEINASE INHIBITOR; STAVUDINE;

ADULT; AGED; ARTICLE; CHEEK; CONTROLLED STUDY; DISEASE SEVERITY; DRUG TOLERABILITY; ECCHYMOSIS; ECHOGRAPHY; EDEMA; ERYTHEMA; FACE; FEMALE; FOLLOW UP; HERPES ZOSTER OPHTHALMICUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMPLANT; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SAFETY; SELF CONCEPT; SKINFOLD THICKNESS; SUBCUTANEOUS NODULE;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; BIOCOMPATIBLE MATERIALS; DRUG THERAPY, COMBINATION; FACE; FEMALE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; LACTIC ACID; MALE; MIDDLE AGED; POLYMERS; PROSTHESES AND IMPLANTS;

EID: 33645100143     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.3.329     Document Type: Article

References (24)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al; HIV Outpatients Study Investigators. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 1998;338:853-860.
2. The CASCADE Collaboration. Survival after introduction of HAART in people with known duration of HIV-1 infection. Lancet. 2000;355:1158-1159.
3. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitor. AIDS. 1998;12:F51-F58.
4. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS. 1999;13:2493-2505.
5. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592-598.
6. Shevitz A, Wanke CA, Falutz J, et al. Clinical perspective on HIV-associated lipodystrophy syndrome: an update. AIDS. 2001;15:1917-1930.
7. Savés M, Raffi F, Capeau J, et al. Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. Clin Infect Dis. 2002;34:1396-1405.
8. Galli M, Veglia F, Angarano G, et al. Gender differences in antiretroviral drug-related adipose tissue alterations. J Acquir Immune Defic Syndr. 2003;34:58-61.
9. Bernasconi E, Boubaker K, Junghans C, et al. Abnormalities of body fat distribution in HIV-infected persons treated with antiretroviral drugs. J Acquir Immune Defic Syndr. 2002;31:50-55.
10. Tien PC, Grunfeld C. What is HIV-associated lipodystrophy? defining fat distribution changes in HIV infection. Curr Opin Infect Dis. 2004;17:27-32.
11. Collins E, Wagneer C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read. 2000;10:546-550.
12. Martinez E, Garcia-Viejo MA, Blanch J, et al. Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf. 2001;24:157-166.
13. Valantin MA, Aubron-Olivier C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS. 2003;17:2471-2477.
14. Moyle GJ, Lysakova L, Brown S, et al. A randomised open-label study of immediate versus delayed polylactic injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med. 2004;5:82-87.
15. Gogolewski S, Javanovic M, Perren SM, et al. Tissue response and in vivo degradation of selected polyhydroxyacids: polylactides (PLA) poly(3-hydroxybutyrate) (PHB), and poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHB/VA). J Biomed Mater Res. 1993;27:1135-1148.
16. Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Med Care. 1991;29:786-798.
17. Mallal SA, John M, Moore CB, et al. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS. 2000;14:1309-1316.
18. Mallon PW, Miller J, Cooper DA, et al. Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS. 2003;17:971-979.
19. Rakotoambinina B, Medioni J, Rabian C, et al. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001;27:443-449.
20. Heath KV, Hogg RS, Singer J, et al. Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based cohort. J Acquir Immune Defic Syndr. 2002;30:440-447.
21. Bogner JR, Vielhauer V, Beckmann RA, et al. Stavudine versus zidovudine and the development of lipodystrophy. J Acquir Immune Defic Syndr. 2001;27:237-244.
22. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis. 2002;34:649-657.
23. Levan P, Nguyen TH, Lallemand F, et al. Correction of facial lipoatrophy in HIV-infected patients on highly active antiretroviral therapy by injection of autologous fatty tissue. AIDS. 2002;16:1985-1987.
24. Talmor M, Hoffman LA, LaTrenta GS. Facial atrophy in HIV-related fat redistribution syndrome: anatomic evaluation and surgical reconstruction. Ann Plast Surg. 2002;49:11-17.